CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: Greater frequency of PRAME-specific CD8+ T cells was evident in patients with AML, CML, and ALL than healthy controls, revealing the potential for developing PRAME as a target for immunotherapy in leukemia.